Role of CNK1, Ephrin B1, GPR19 and SMURF1 in breast cancer early diagnosis, metastasis and drug resistance
Abdrabou, A., Radwan, S., El shimy, R., El Mesallamy, H. (2021). Role of CNK1, Ephrin B1, GPR19 and SMURF1 in breast cancer early diagnosis, metastasis and drug resistance. EKB Journal Management System, 64(7), 3961-3969. doi: 10.21608/ejchem.2021.77940.3833
Afnan Abdrabou; Sara M Radwan; Reham A El shimy; Hala El Mesallamy. "Role of CNK1, Ephrin B1, GPR19 and SMURF1 in breast cancer early diagnosis, metastasis and drug resistance". EKB Journal Management System, 64, 7, 2021, 3961-3969. doi: 10.21608/ejchem.2021.77940.3833
Abdrabou, A., Radwan, S., El shimy, R., El Mesallamy, H. (2021). 'Role of CNK1, Ephrin B1, GPR19 and SMURF1 in breast cancer early diagnosis, metastasis and drug resistance', EKB Journal Management System, 64(7), pp. 3961-3969. doi: 10.21608/ejchem.2021.77940.3833
Abdrabou, A., Radwan, S., El shimy, R., El Mesallamy, H. Role of CNK1, Ephrin B1, GPR19 and SMURF1 in breast cancer early diagnosis, metastasis and drug resistance. EKB Journal Management System, 2021; 64(7): 3961-3969. doi: 10.21608/ejchem.2021.77940.3833

Role of CNK1, Ephrin B1, GPR19 and SMURF1 in breast cancer early diagnosis, metastasis and drug resistance

Egyptian Journal of Chemistry
Article 69, Volume 64, Issue 7, July 2021, Page 3961-3969  XML PDF (703.32 K)
Document Type: Original Article
DOI: 10.21608/ejchem.2021.77940.3833
View on SCiNiTO View on SCiNiTO
Authors
Afnan Abdrabouorcid 1; Sara M Radwanorcid 2; Reham A El shimyorcid 3; Hala El Mesallamy email orcid 4
1Biochemistry department, faculty of Pharmacy, Ahram Canadian University, Cairo, Egypt.
2Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
3Clinical and chemical Pathology, National Cancer Institute NCI, Cairo University, Cairo, Egypt.
4Biochemistry, Faculty of Pharmacy, Sinai University, Sinai, Egypt
Abstract
Abstract:
Background: The extracellular signal-regulated kinase (ERK) pathway is a key signaling pathway involved in the regulation of normal cell proliferation, survival and differentiation. However, aberrant regulations of the ERK pathway contribute to cancer and other human diseases.
Objective: This study was designed to investigate the role of some ERK pathway effectors such as the connector enhancer of kinase suppressor of Ras1 (CNK1), Ephrin B1, G protein-coupled receptor 19 (GPR19) and SMAD ubiquitination regulatory factor 1 (SMURF1) in breast cancer (BC) diagnosis and metastasis risk prediction.
Methods: The study involved 50 (ER-PR-Her2+=6, ER+PR+Her2+=11, ER-PR-HER2-=8, ER+PR+Her2-=25) newly diagnosed BC patients, 15 chemotherapy resistant BC patients, 15 benign breast tumor patients and 10 controls. All total 65 BC patients (including the chemotherapy resistant group) were subdivided into two groups: metastatic BC (17 patients), and non-metastatic BC group (48 patients). CNK1, Ephrin B1, GPR19 and SMURF1 serum levels were analyzed using ELISA.
Results: The study revealed significantly higher serum levels of CNK1, Ephrin B1, GPR19 and SMURF1 in all malignant groups (ER-PR-Her2+, ER+PR+Her2+, ER-PR-HER2-, ER+PR+Her2-), as well as a significant elevation in the chemotherapy resistant BC group as compared to non-resistant group (P < 0.001). They also revealed excellent value for de novo BC diagnosis and metastasis prediction.
Conclusion: CNK1, Ephrin B1, GPR19 and SMURF1 may be considered as novel biomarkers for BC diagnosis and prediction of metastasis risk.
Keywords
Keywords: Breast cancer; ERK pathway; CNK1; Ephrin B1; GPR19; SMURF1
Statistics
Article View: 463
PDF Download: 236